---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-269486"
form_type: "8-K"
ticker: "ATYR"
cik: "0001339970"
company_name: "aTYR PHARMA INC"
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:28:19.995685+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# aTyr reports Q3 results; Phase 3 efzofitimod miss but plans FDA meeting

## Summary
- Phase 3 EFZO-FIT missed primary endpoint of corticosteroid dose reduction at week 48; 5.0 mg/kg showed benefit on multiple quality-of-life measures.
- Company plans FDA meeting in Q1 2026 to discuss path forward for efzofitimod in pulmonary sarcoidosis.
- Phase 2 EFZO-CONNECT enrollment in SSc-ILD expected to complete H1 2026; interim data reported Q2 2025.
- Cash, equivalents, restricted cash and investments $92.9M as of Sep 30, 2025.
- R&D expenses $22.1M, G&A $4.8M for Q3 2025.

## SEC filing metadata
- accession: 0001193125-25-269486
- form_type: 8-K
- ticker: ATYR
- cik: 0001339970
- company_name: aTYR PHARMA INC
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339970/000119312525269486/0001193125-25-269486-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339970/000119312525269486/atyr-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-269486
- JSON: https://secwatch.observer/filing/0001193125-25-269486.json
- Plain text: https://secwatch.observer/filing/0001193125-25-269486.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.